Last edition
News about "Contingent Value Right (CVR) "
XOMA Royalty to Acquire Generation Bio
The acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna.
Contingent Value Right (CVR) | 17/12/2025 | By News Bureau | 114
Cycle Pharmaceuticals to Acquire Applied Therapeutics
The acquisition positions Cycle Pharmaceuticals to strengthen its rare disease portfolio, adding Applied Therapeutics’ promising CNS-penetrant aldose reductase inhibitor, govorestat, which targets severe unmet needs in central nervous system metabolic disorders.
Contingent Value Right (CVR) | 12/12/2025 | By Akanki | 141
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy